PLK1 expression in AML-NS8 cells and activity of PLK1 inhibitor NMS-937 <i>in vitro</i> and <i>in vivo</i>.
Alessia Casolaro(Nerviano Medical Sciences), Rachele Alzani(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia), Josée Golay(Azienda Ospedaliero Universitaria Ospedali Riuniti), Silvia Bungaro(University of Milano-Bicocca), Martino Introna(Mario Negri Institute for Pharmacological Research), Francesco Marchesi(Nerviano Medical Sciences), Marco Losa(Vita-Salute San Raffaele University), Alice Pezzoni(Fondazione Humanitas per la Ricerca), Gemma Texidó(Nerviano Medical Sciences), Clara Albanese(University of L'Aquila), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Barbara Valsasina(Nerviano Medical Sciences), Veronica Patton(University of L'Aquila), Enrico Pesenti, Sabrina Cribioli(Nerviano Medical Sciences), Roberta Ceruti(Nerviano Medical Sciences), Ursula Giussani
Cited by 0
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|627